Ionic versus nonionic contrast media: Safety,tolerance, and rationale for use |
| |
| Authors: | Bruce L. McClennan M.D. |
| |
| Affiliation: | 1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway, 63110, St. Louis, MO, USA
|
| |
| Abstract: | ![]()
After several years of clinical experience worldwide and numerous high-quality, randomized controlled trials in humans, the marked improvement in patient tolerance and safety of low osmolar contrast media (ionic and nonionic) has been demonstrated [1–5]. Iohexol (Omnipaque), Iopamidol (Isovue), Ioxaglate (Hexabrix), and Ioversol (Optiray) are all now available in the United States. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
